NAD biology, supplements and translation · Claim Check
NAD precursors raise some metabolites; human longevity benefits remain unproven
Nicotinamide riboside, nicotinamide mononucleotide, niacin and intravenous NAD are often discussed as one intervention. They are not interchangeable, and changing an NAD-related measurement is not the same as improving healthspan.
Source, correction-status, evidence, safety and prose reviews were completed July 31, 2026.
Evidence box
Target engagement is repeatable; meaningful human aging outcomes are not established
- Study type
- Small randomized trials plus systematic review and registry context
- Studied in
- Mostly middle-aged or older adults with differing health profiles
- Participants / sample
- Featured trials include 24 completers and 13 crossover participants; NMN review totals 342
- Publication status
- Peer reviewed; registry and FDA records clearly separated
- Outcome type
- Metabolites, physiology and short-term function—not lifespan
- Development stage
- Dietary supplements and experimental uses; no FDA anti-aging indication
- Conflicts / funding
- Industry-supplied products or company-employed authors appear in several studies
- Our assessment
- Early and mixed: biochemical target engagement without established healthspan benefit
- Reporting confidence
- High for identifiers and null findings; low for cross-product or longevity inference
The bottom line
Oral nicotinamide riboside can alter NAD-related metabolites in humans. In two small crossover trials it did not produce broad improvements in insulin sensitivity, mitochondrial function, cardiovascular measures, motor function or exercise capacity. Nicotinamide mononucleotide has separate evidence; a 2024 synthesis of eight randomized trials found no glucose or lipid benefit. None of these results establishes longer life. (NR pilot; NR counterevidence)
Why this matters
NAD participates in energy metabolism and cellular signaling, and levels change with age in some tissues and models. The translation error happens when a plausible pathway, an increased blood or muscle metabolite, and a clinical benefit are treated as the same finding. They are separate steps.
What researchers did
A six-week crossover pilot enrolled 30 healthy middle-aged and older adults and analyzed 24 completers. Another six-week crossover studied 13 adults with overweight or obesity using detailed metabolic tests and muscle biopsies. Other trials differ in age, cognition, obesity, exercise, precursor, formulation and endpoint. NCT04823260 records a completed 90-participant NMN study, but a registry entry is not a verdict.
What they found
The first NR trial showed biochemical target engagement. Exploratory blood-pressure and arterial-stiffness signals did not survive its multiple-comparison threshold, and motor and aerobic capacity did not improve. In the 13-person trial, muscle NAD-related metabolites changed, while insulin sensitivity, mitochondrial function, ambulatory blood pressure, inflammation and several cardiac measures did not. Later small trials have also reported null mitochondrial, muscle, cognition or primary blood-pressure outcomes.
How strong is the evidence?
Randomization and crossover designs help with short-term comparisons, but samples are tiny, durations short and outcomes numerous. A biomarker response can confirm that a compound reached a pathway; it cannot by itself establish disease prevention, function, healthspan or lifespan. Product purity, formulation and route also limit generalization.
What this evidence does not show
It does not show that NR, NMN, niacin and intravenous NAD have equivalent effects, that raising a blood metabolite restores tissue aging, or that any featured product prevents dementia, frailty or death. Secondary or exploratory signals in small trials are not established benefits. Animal lifespan findings do not substitute for human outcomes.
Safety and conflicts
Dietary supplements are not FDA-preapproved for safety or effectiveness before sale. Several trials received branded study material or included company-employed authors. The 13-person NR trial reported product supplied by ChromaDex alongside public funding and no author conflicts. FDA has separately warned that food-grade NAD is unsuitable for sterile compounding; oral-supplement evidence cannot be transferred to intravenous products.
What happens next
Useful studies would preregister one clinically meaningful primary outcome, enroll enough participants, specify the exact compound and formulation, track adverse effects and durability, and publish full results regardless of direction. Until then, “raises NAD-related metabolites” is the defensible claim; “slows human aging” is not.
Primary sources
Sources, roles and limits
- Martens et al., NR crossover pilot
- Identifier
- PMID:29599478 · PMCID:PMC5876407 · DOI:10.1038/s41467-018-03421-7 · NCT02921659
- Role
- Primary target-engagement trial
- Limitation
- 24 completers; exploratory vascular signals did not survive the multiple-comparison threshold.
- Remie et al., NR metabolic crossover trial
- Identifier
- PMID:32320006 · PMCID:PMC7398770 · DOI:10.1093/ajcn/nqaa072 · NCT02835664
- Role
- Primary metabolic counterevidence
- Limitation
- 13 participants, six weeks; biochemical changes without broad metabolic benefit.
- 2024 NMN randomized-trial meta-analysis
- Identifier
- PMID:39531138
- Role
- Separate-compound evidence synthesis
- Limitation
- Eight small heterogeneous trials; no glucose or lipid benefit and no lifespan endpoint.
- NCT04823260 NMN study record
- Identifier
- NCT04823260
- Role
- Operational trial status and endpoint context
- Limitation
- Registry inclusion and completed status are not government validation or proof of benefit.
- FDA dietary-supplement regulatory overview
- Identifier
- FDA consumer update
- Role
- Regulatory context
- Limitation
- General regulation source; does not evaluate a specific product.
- FDA warning on compounded NAD products
- Identifier
- FDA compounding safety communication
- Role
- Route- and quality-specific safety context
- Limitation
- Compounding warning should not be generalized into an efficacy result for oral precursors.
Connected topics
Continue through the knowledge system
Disclosures and history
- July 31, 2026 — discovery, counterevidence and claim-level integration passes completed before prose drafting.
- July 31, 2026 — identifiers, correction status, conflicts, evidence scope and safety context verified; standing publication authorization applied.